JO3039B1 - طريقة ومركب لعلاج فرط ضغط العين والجلوكوما - Google Patents

طريقة ومركب لعلاج فرط ضغط العين والجلوكوما

Info

Publication number
JO3039B1
JO3039B1 JOP/2009/0192A JOP20090192A JO3039B1 JO 3039 B1 JO3039 B1 JO 3039B1 JO P20090192 A JOP20090192 A JO P20090192A JO 3039 B1 JO3039 B1 JO 3039B1
Authority
JO
Jordan
Prior art keywords
glaucoma
ocular hypertension
composition
treating ocular
aqueous composition
Prior art date
Application number
JOP/2009/0192A
Other languages
English (en)
Inventor
Olli Oksala
Pertti Pellinen
Timo Reunamaki
Kari Lehmussaari
Original Assignee
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3039(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd
Application granted granted Critical
Publication of JO3039B1 publication Critical patent/JO3039B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة مائية خاصة بالعيون محتوية على نظائر PGF2a لعلاج ارتفاع ضغط الدم في العين والجلوكوما، وبطريقة لعلاج ارتفاع ضغط الدم في العين والجلوكوما عن طريق اعطاء التركيبة المذكروة الى مريض في حاجة الى هذا العلاج، وبطريقة لزيادة قابلية نظائر PGF2a للذوبان في الماء وثباتها في تركيبة مائية
JOP/2009/0192A 2008-05-30 2009-05-27 طريقة ومركب لعلاج فرط ضغط العين والجلوكوما JO3039B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
JO3039B1 true JO3039B1 (ar) 2016-09-05

Family

ID=39940592

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0192A JO3039B1 (ar) 2008-05-30 2009-05-27 طريقة ومركب لعلاج فرط ضغط العين والجلوكوما

Country Status (27)

Country Link
US (3) US9999593B2 (ar)
EP (8) EP2127638A1 (ar)
JP (9) JP2011521943A (ar)
KR (5) KR101650006B1 (ar)
CN (1) CN102083413B (ar)
AR (2) AR071937A1 (ar)
AU (1) AU2009252210C1 (ar)
BR (1) BRPI0913109B8 (ar)
CA (2) CA2724194C (ar)
CY (2) CY1115565T1 (ar)
DK (4) DK2772249T3 (ar)
EA (1) EA023661B1 (ar)
ES (6) ES2907982T3 (ar)
GE (1) GEP20156220B (ar)
HR (4) HRP20220361T1 (ar)
HU (3) HUE049923T2 (ar)
JO (1) JO3039B1 (ar)
LT (3) LT2772249T (ar)
MX (1) MX2010012987A (ar)
MY (1) MY159463A (ar)
PL (4) PL2306977T3 (ar)
PT (4) PT3714877T (ar)
SG (1) SG191628A1 (ar)
SI (4) SI2772249T1 (ar)
TW (1) TWI432202B (ar)
UA (1) UA102257C2 (ar)
WO (1) WO2009145356A1 (ar)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US10154923B2 (en) * 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
RU2624534C2 (ru) 2010-07-29 2017-07-04 Аллерган, Инк. Растворы биматопроста и тимолола, не содержащие консервантов
US9061034B2 (en) * 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
AU2011282679A1 (en) * 2010-07-29 2013-03-07 Allergan, Inc. Preservative free bimatoprost solutions
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
EP2618810B1 (en) * 2010-09-21 2016-11-23 S & V Technologies GmbH Cosmetic composition
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
KR20140038404A (ko) * 2011-04-12 2014-03-28 가부시키가이샤 아루떼꾸 우에노 수성 안과용 조성물
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
WO2014032026A1 (en) 2012-08-24 2014-02-27 Mitra Ashim K Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
EP3091985B1 (en) 2014-01-10 2024-05-08 Manistee Therapeutics, Inc. Prostanglandins for topical use in the treatment of migraines.
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
ES2747302T3 (es) 2015-06-09 2020-03-10 Medproject Pharma Entw Und Vertriebsgesellschaft Mbh Gel oftálmico de bimatoprost aplicable en gotas
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
WO2017078953A1 (en) * 2015-11-06 2017-05-11 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
PL3373976T3 (pl) 2015-11-10 2024-06-24 Sun Pharmaceutical Industries Limited Preparaty do stosowania miejscowego i ich zastosowanie
MX2018010395A (es) 2016-02-29 2018-11-29 Sun Pharma Global Fze Formulaciones topicas que contienen cliclosporina y usos de las mismas.
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
KR20190128657A (ko) * 2017-03-27 2019-11-18 코와 가부시키가이샤 의약 제제
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
US11382887B2 (en) 2017-06-22 2022-07-12 Ys Life Science Co. Ltd. Ophthalmic composition for glaucoma treatment
EP4338751B1 (en) * 2017-12-21 2025-09-03 Santen Pharmaceutical Co., Ltd. Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
WO2020013717A1 (en) 2018-07-09 2020-01-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Ophthalmic dispensing device
JP7599838B2 (ja) * 2019-04-10 2024-12-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性医薬組成物
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
CN116687842A (zh) * 2022-02-28 2023-09-05 山东新时代药业有限公司 一种拉坦前列素滴眼液及其制备方法
US20250213510A1 (en) * 2022-03-25 2025-07-03 Tsubota Laboratory, Inc. Aqueous Composition
CN119384280A (zh) * 2022-06-16 2025-01-28 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
TW202444342A (zh) * 2023-03-24 2024-11-16 日商坪田實驗室股份有限公司 水性組成物
WO2024232425A1 (ja) * 2023-05-11 2024-11-14 テイカ製薬株式会社 プロスタグランジンＦ２α誘導体の含有率低下が抑制されている製品
JP7757564B1 (ja) 2024-06-28 2025-10-21 東亜薬品株式会社 水性組成物
GR1011143B (el) * 2025-04-11 2026-03-02 Ιουλια Τσετη Οφθαλμικο διαλυμα προσταγλανδινης χωρις συντηρητικα

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
EP0286903B2 (en) 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
CA2237898A1 (en) * 1995-11-17 1997-05-29 Louis Desantis Jr. Combination therapy for treating glaucoma
EP0930296B2 (en) 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Fluorinated prostaglandin derivatives and medicines
CA2273837C (en) 1996-12-09 2003-12-30 Bausch & Lomb Incorporated Single-use flexible container
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
DE69834638T2 (de) * 1997-10-13 2007-05-10 R-Tech Ueno, Ltd. Zusammensetzung zur Behandlung von Augenhypertension oder Glaukom
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
DE69922916T2 (de) * 1998-07-14 2005-06-09 Alcon Manufacturing Ltd., Fort Worth Polypropylenbasierte behälter für prostaglandin-enthaltende produkte
WO2000018316A2 (en) 1998-09-25 2000-04-06 Alcon Laboratories, Inc. Sustained release, and comfortable ophthalmic composition and method for ocular therapy
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
HUP0200898A3 (en) 1999-04-06 2005-09-28 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
AU2001264261A1 (en) 2000-06-19 2002-01-02 Santen Pharmaceutical Co. Ltd. Aseptics
CA2422031C (en) 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
TW586946B (en) 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
JP4402591B2 (ja) 2002-07-16 2010-01-20 千寿製薬株式会社 薬液容器及びその製造方法
CA2707067C (en) * 2002-09-09 2013-07-16 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
ATE450264T1 (de) * 2003-07-31 2009-12-15 Santen Pharmaceutical Co Ltd Prostaglandin enthaltendes produkt
US20050287325A1 (en) * 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
EP1655021B1 (en) * 2004-11-09 2008-10-29 Novagali Pharma SA Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
US7562796B2 (en) 2004-11-24 2009-07-21 Holopack International Corp. Dispensing container with flow control system
ES2588581T3 (es) 2004-12-09 2016-11-03 Santen Pharmaceutical Co., Ltd. Producto que contiene prostaglandina con átomo de flúor en su molécula
DK1829545T3 (da) 2004-12-24 2012-07-23 Santen Pharmaceutical Co Ltd Produkter indeholdende prostaglandin-F2alfa-derivat
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
CN101222939B (zh) 2005-07-13 2010-11-24 参天制药株式会社 眼科用防腐组合物
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
PT1937212E (pt) 2005-10-10 2010-11-30 Novagali Pharma Sa Emulsões oftálmicas contendo prostaglandinas
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
JP2016065095A (ja) 2016-04-28
LT2772249T (lt) 2017-09-11
JP6649992B2 (ja) 2020-02-19
HRP20220361T1 (hr) 2022-05-13
HRP20200998T1 (hr) 2020-10-16
BRPI0913109A2 (pt) 2017-06-20
MX2010012987A (es) 2011-02-24
EP4512424A2 (en) 2025-02-26
JP2021120412A (ja) 2021-08-19
GEP20156220B (en) 2015-01-26
MY159463A (en) 2017-01-13
KR102114401B1 (ko) 2020-05-25
US20180289618A1 (en) 2018-10-11
JP2020073574A (ja) 2020-05-14
ES2627837T3 (es) 2017-07-31
PL2306977T3 (pl) 2015-01-30
US10864159B2 (en) 2020-12-15
EP4512424B1 (en) 2026-03-18
SI3714877T1 (sl) 2022-05-31
DK2772249T3 (en) 2017-07-17
EA201071413A1 (ru) 2011-06-30
JP2018154656A (ja) 2018-10-04
KR20190067272A (ko) 2019-06-14
EP4289446B1 (en) 2025-02-12
EP3205334A1 (en) 2017-08-16
EP4035656B1 (en) 2023-11-22
JP2017178957A (ja) 2017-10-05
PL3714877T3 (pl) 2022-05-16
JP6356868B2 (ja) 2018-07-11
JP6148317B2 (ja) 2017-06-14
LT3714877T (lt) 2022-04-11
HUE058079T2 (hu) 2022-06-28
JP2024079852A (ja) 2024-06-11
PL2772249T3 (pl) 2017-10-31
DK3205334T3 (da) 2020-07-13
EP2772249B1 (en) 2017-05-03
CA2724194A1 (en) 2009-12-03
EP4512424A3 (en) 2025-03-05
ES2808050T3 (es) 2021-02-25
EP4289446A2 (en) 2023-12-13
EP2127638A1 (en) 2009-12-02
KR101988642B1 (ko) 2019-06-12
ES3014089T3 (en) 2025-04-16
PT3205334T (pt) 2020-07-31
SI2772249T1 (sl) 2017-08-31
KR20110011707A (ko) 2011-02-08
DK3714877T3 (da) 2022-02-14
EP3714877B1 (en) 2022-01-26
HRP20140979T1 (hr) 2014-11-21
US9999593B2 (en) 2018-06-19
US20110152264A1 (en) 2011-06-23
DK2306977T3 (da) 2014-09-15
AR120961A2 (es) 2022-04-06
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
WO2009145356A1 (en) 2009-12-03
KR101650006B1 (ko) 2016-08-22
EP2772249A1 (en) 2014-09-03
EP2306977B1 (en) 2014-08-13
CN102083413B (zh) 2013-11-06
EP2306977A1 (en) 2011-04-13
EP3714877A1 (en) 2020-09-30
AU2009252210B2 (en) 2014-10-16
JP2014133765A (ja) 2014-07-24
AR071937A1 (es) 2010-07-28
JP7520285B2 (ja) 2024-07-23
EP4289446A3 (en) 2024-01-10
SG191628A1 (en) 2013-07-31
UA102257C2 (uk) 2013-06-25
JP7265584B2 (ja) 2023-04-26
ES2968837T3 (es) 2024-05-14
ES2495316T3 (es) 2014-09-17
KR101820816B1 (ko) 2018-01-22
JP2011521943A (ja) 2011-07-28
KR20160102319A (ko) 2016-08-29
PT3714877T (pt) 2022-03-10
HRP20170769T1 (hr) 2017-08-11
LT3205334T (lt) 2020-09-25
TW201000104A (en) 2010-01-01
AU2009252210A1 (en) 2009-12-03
KR20180008905A (ko) 2018-01-24
TWI432202B (zh) 2014-04-01
KR102246598B1 (ko) 2021-04-30
CY1115565T1 (el) 2017-01-04
CY1120351T1 (el) 2019-07-10
PT2772249T (pt) 2017-08-08
CN102083413A (zh) 2011-06-01
US20210059931A1 (en) 2021-03-04
BRPI0913109B1 (pt) 2019-10-22
CA2965185A1 (en) 2009-12-03
PL3205334T3 (pl) 2020-11-02
ES2907982T3 (es) 2022-04-27
KR20200057801A (ko) 2020-05-26
JP2023085558A (ja) 2023-06-20
AU2009252210C1 (en) 2016-04-14
HUE033103T2 (en) 2017-11-28
JP6889789B2 (ja) 2021-06-18
EA023661B1 (ru) 2016-06-30
BRPI0913109B8 (pt) 2021-05-25
EP4035656A1 (en) 2022-08-03
HUE049923T2 (hu) 2020-11-30
ES2627837T8 (es) 2018-02-26
PT2306977E (pt) 2014-09-22
EP3205334B1 (en) 2020-04-29
CA2724194C (en) 2017-06-27

Similar Documents

Publication Publication Date Title
MY159463A (en) Method and composition for treating ocular hypertension and glaucoma
PH12013501579A1 (en) Androgen composition for treating an opthalmic condition
PH12013501808B1 (en) High concentration olopatadine ophthalmic composition
WO2013037479A8 (en) Ophthalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid
NZ608202A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
EA201200762A1 (ru) Применение простагландинов f2-альфа и аналогов для заживления повреждений роговицы и конъюнктивы
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EP2515917A4 (en) COMPOSITIONS AND METHODS FOR EYE-UP
UA113627C2 (xx) Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
EA201190337A1 (ru) Способ лечения
PH12014500179A1 (en) Fixed dose combination of bimatoprost and brimonidine
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
EA201490845A1 (ru) Улучшенная сшивающая композиция, доставляемая способом ионтофореза, пригодная для лечения кератоконуса
ECSP12012033A (es) Triple combinación para bajar la presión intraocular
MY160383A (en) Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
MX2019005321A (es) Derivados de prostaglandina que liberan oxido nitrico para el tratamiento de glaucoma de tension normal.
MY157434A (en) Method for improving bioavailability of latanoprost
WO2012024419A3 (en) Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
MX2010008308A (es) Tratamiento para trastornos relacionados con los ojos.
MX2012005447A (es) Combinacion farmacéutica de compuesto de prostaglandina y nsaid (medicamentos antiinflamantorios no esteroideos) para el tratamiento de glaucoma e hipertensión ocular.
TN2013000081A1 (en) Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension
TN2010000368A1 (en) Treatment for ocular-related disorders
UA92208C2 (ru) Способ лечения диабетической ангионевроретинопатии
GR1008250B (el) Οφθαλμικο σκευασμα αναλογου προσταγλανδινης και μεθοδος παρασκευης αυτου